News
SLGL
6.90
-0.29%
-0.02
Weekly Report: what happened at SLGL last week (0602-0606)?
Weekly Report · 4d ago
Weekly Report: what happened at SLGL last week (0526-0530)?
Weekly Report · 06/02 10:17
Weekly Report: what happened at SLGL last week (0519-0523)?
Weekly Report · 05/26 10:16
Sol-Gel Technologies Reports Q1 2025 Financial Results
TipRanks · 05/24 03:51
Sol-Gel Technologies reports Q1 EPS ($3.20) vs. ($2.30) last year
TipRanks · 05/23 11:25
Sol-Gel Technologies sees cash runway into 1Q27
TipRanks · 05/23 11:25
Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate
Benzinga · 05/23 11:25
Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses
NASDAQ · 05/23 11:20
SOL GEL TECHNOLOGIES: Q1 NET LOSS PER SHARE $3.2
Reuters · 05/23 11:15
SOL GEL TECHNOLOGIES LTD - SOL-GEL EXPECTS CASH RESOURCES TO FUND REQUIREMENTS INTO Q1 2027
Reuters · 05/23 11:15
Sol-Gel Reports First Quarter 2025 Results
Barchart · 05/23 06:15
Sol-Gel Technologies Regains Nasdaq Compliance
TipRanks · 05/22 20:28
Weekly Report: what happened at SLGL last week (0512-0516)?
Weekly Report · 05/19 10:11
Weekly Report: what happened at SLGL last week (0505-0509)?
Weekly Report · 05/12 10:12
Biotech Alert: Searches spiking for these stocks today
TipRanks · 05/08 16:25
Sol Gel Technologies trading resumes
TipRanks · 05/05 18:25
Sol Gel Technologies trading halted, volatility trading pause
TipRanks · 05/05 18:20
Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance
TipRanks · 05/05 12:04
Weekly Report: what happened at SLGL last week (0428-0502)?
Weekly Report · 05/05 10:13
More
Webull provides a variety of real-time SLGL stock news. You can receive the latest news about Sol Gel Technolg through multiple platforms. This information may help you make smarter investment decisions.
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.